Xvivo System model X2 —  The 21st Century GMP Quality Platform for processing and producing clinical grade cells.

June 1, 2020

author: BioSpherix Medical
Next Generation Isolators at Canadian Hospitals to begin COVID-19 clinical trials
  • Utilizing Next Generation Isolator technology from BioSpherix Medical, hospitals in both Ottawa and Toronto were able to rapidly shift gears and change their existing GMP facility infrastructure (both are using Next Gen. isolators) to begin a clinical trial of MSCs for treating COVID-19 ARDS:
  • https://oirm.ca/news_events/stem-cell-trial-covid19/

BioSpherix will be adapting all operations to the pandemic and recent New York State Covid-19 Business Mandates. We apologize for any inconveniences this may cause.